Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2006-12-05
2006-12-05
Chan, Christina (Department: 1644)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C530S303000, C530S350000
Reexamination Certificate
active
07144707
ABSTRACT:
In one aspect of the present invention there is provided a method for determining the risk of developing a complication of preterm birth in a patient born before 40 weeks of gestation or weighing 10% less than the average for the patient's gestational age. The method involves measuring serum IGF-I and/or IGF-I binding protein levels after birth of the patient to obtain an IGF-I or IGF-I binding protein level; and correlating said IGF-I or IGF-I binding protein level with an in utero baseline level of IGF-I or IGF-I binding protein based on gestational age matched mean levels in utero, wherein an IGF-I or IGF-I binding protein level below the mean gestational age in utero level indicates the patient is at an increased risk of developing a complication of preterm birth. The complications of preterm birth include retinopathy of prematurity, developmental delay, mental retardation, bronchopulmonary dysplasia, and intraventricular hemorrhage. Methods for treating/preventing complications of preterm birth are also provided.
REFERENCES:
patent: 6034059 (2000-03-01), Fryklund et al.
patent: WO 03/012043 (2003-02-01), None
Lineham et al., “Circulating insulin-like growth factor I levels in newborn premature and full-term infants followed longitudinally,” early Human development, 1986, 13:37-46.
Verhaeghe et al., “C-peptide, insulin-like growth factors I and II, and insulin-like grwoth factor binding protein-1 in umbilical cord serum: Correlations with birth weight,” Am J Obstet Gynecol, 1993, 169:89-97.
Hellstrom et al., “Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth”, Pediatrics, 2003, 112:1016-1020.
Lofqvist et al., “Postnatal head growth deficit among premature infants parallels retionopathy and insulink-like growth factor-1 deficit” Pediatrics, 2006, 117:1930-1938.
Msall et al. “Severity of Neonatal Retinopathy of Prematurity is Predictive of Neurodevelopment Functional Outcome at Age 5.5 Years” Pediatrics, 2000, 106:998-1005.
Smith LE, “IGF-1 and retinopathy of prematurity in the preterm infant” Biol. Neonate, 2005 88:237-244.
Aiello, L.P. et al.;Proc Natl. Acad. Sci. U S A;92:10457-61 (1995).
Alon, T. et al.;Nature Medicine;1(10):1024-8 (1995).
Ashton, N.;Am J. Ophthalmol.;62(3);:412-35 (1966).
Baker, J. et al.; Cell; 75:73-82 (1993).
Baxter, R.C. et al.; Biochem. Biophys. Res. Comm.; 139(3):1256-1261 (1986).
Blum, W.F. et al.; Modern Concepts In Insulin-Like Growth Factors (E. M. Spencer, ed., Elsevier, New York); pp. 381-393 (1991).
Davis, J.M. et al.; Neonatology: Pathophysiology and Management of the Newborn; pp. 453-477 (1994).
de Lacerda, L. et al.; Clin. Endocrinol.; 51:541-550 (1999).
Flynn, J.T. et al.; Arch. Ophthalmol.; 95:217-223 (1977).
Frank L., Clin. Perinatol.; 19:541-562 (1992).
Gluckman, P.D. et al.; Hormone Research; 48:11-16 (1997).
Hack, M. et al.; The Future of Children; 5:176-196 (1995).
Kinsey, V.E. et al.; Pediatrics; 60(5):655-668 (1977).
Lucey, J.F. et al.; Pediatrics; 73(1):82-96 (1984).
Northway, W.H.; Pediatrics; 89(5):969-973 (1992).
Ozaki, H. et al.; American Journal of Pathology; 156(2):697-707 (2000).
Penn, J.S. et al.; Invest. Ophthalmol. Vis. Sci.; 35(9):3429-3435 (1994).
Pierce, E. A. et al.; Arch Ophthalmol;. 114:1219-1228 (1996).
Rinderknecht, E. et al.; Proc. Natl. Acad. Sci. USA; 73(7):2365-2369 (1976).
Robinson, G.S. et al.; Proc. Natl. Acad. Sci. USA; 93:4851-4856 (1996).
Rush, M.G. et al.; Clinics in Perinatology; 19(3):563-590 (1992).
Simons, B.D. et al.; International Ophthalmology Clinics; 39:29-48 (1999).
Sommer, A. et al.; Modern Concepts Of Insulin-Like Growth Factors (E. M. Spencer, ed., Elsevier, New York); pp. 715-728 (1991).
Southall, D.P. et al.; Archives of Disease in Childhood; 65:1089-1095 (1990).
Stone, J. et al.; The Journal of Neuroscience; 15(7):4738-4747 (1995).
Woods, K.A. et al.; New England Journal of Medicine; 335(18):1363-1367 (1996).
Hellström Ann
Smith Lois
Chan Christina
Children's Medical Center Corporation
Nixon & Peabody LLP
Szperka Michael
LandOfFree
Determination of risk and treatment of complications of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Determination of risk and treatment of complications of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Determination of risk and treatment of complications of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3711104